About: Treatment of COVID‐19 with pentoxifylline: Could it be a potential adjuvant therapy?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Treatment of COVID‐19 with pentoxifylline: Could it be a potential adjuvant therapy? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Treatment of COVID‐19 with pentoxifylline: Could it be a potential adjuvant therapy?
Creator	Fattahi, Nima Goodarzi, Azadeh Hanifiha, -Melika Hanifiha, Melika Mozafarpoor, -Samaneh Mozafarpoor, Samaneh Sadeghzadeh-Bazargan, Afsaneh Seirafianpour, : -Farnoosh Seirafianpour, Farnoosh
source	Medline; PMC
abstract	The world is facing a viral pandemic of a new coronavirus called COVID‐19. Pentoxifylline is a methyl‐xanthine and it inhibits phosphodiesterase IV (PDE IV). This drug is known for its unique features as an immunomodulatory and anti‐inflammatory agent, also it could have antiviral affects. This is a scoping review, in which all related articles on COVID‐19 and the probable benefits of Pentoxifylline against COVID‐19 pathogenesis, in Medline, Scopus, Web of Sciences and Google Scholar up to March 20, 2020 with proper keywords including: pentoxifylline, Pentoxil, COVID‐19, coronavirus, treatment, anti‐inflammatory, immunomodulatory, anti‐fibrosis, oxygenation, circulation, bronchodilator, ARDS and organ failure. We found many confirmatory data on proper efficacy of pentoxifylline n controlling COVID‐19 and its consequences. The antiviral, anti‐inflammatory, anti‐oxidative, immune‐modulatory, bronchodilator and respiratory supportive effects and protective roles in organ failures of PTX, along with its main functions means better circulation‐oxygenation properties, low price and safety, make it a promising drug to be considered for covid‐19 treatment, especially as an adjuvant therapy in combination with other drugs. This article is protected by copyright. All rights reserved.
has issue date	2020-05-30(xsd:dateTime)
bibo:doi	10.1111/dth.13733
bibo:pmid	32473070
has license	no-cc
sha1sum (hex)	fbb866bdf7f007c55c390da289ef91a2b7b0386c
schema:url	https://doi.org/10.1111/dth.13733
resource representing a document's title	Treatment of COVID‐19 with pentoxifylline: Could it be a potential adjuvant therapy?
has PubMed Central identifier	PMC7300917
has PubMed identifier	32473070
schema:publication	Dermatol Ther
resource representing a document's body	covid:fbb866bdf7f007c55c390da289ef91a2b7b0386c#body_text
is schema:about of	named entity 'COVID-19' named entity 'COVID-19' named entity 'adjuvant therapy' named entity 'COVID-19' named entity 'COVID-19' named entity 'COVID-19' named entity 'pentoxifylline' named entity 'end-organ damage' named entity 'microcirculation' named entity 'pharmacologic' named entity 'anti-viral' named entity 'bronchodilator' named entity 'erythrocyte' named entity 'acute respiratory distress syndrome' named entity 'glycosaminoglycan' named entity 'adjuvant therapies' named entity 'pentoxifylline' named entity 'antiinflammatory' named entity 'SARS-related coronavirus' named entity 'COVID' named entity 'proinflammatory' named entity 'antiinflammatory' named entity 'TNFα' named entity 'fibrinogen' named entity 'Trental' named entity 'adhesion' named entity 'antiviral' named entity 'leukocyte' named entity 'ICUs' named entity 'COVID' named entity 'alpha-2 macroglobulin' named entity 'Pentoxifylline' named entity 'collagen' named entity 'homeostasis' named entity 'infection' named entity 'mechanism of action' named entity 'hemorheology' named entity 'COVID' named entity 'leukocytes' named entity 'rheological' named entity 'pentoxifylline' named entity 'COVID' named entity 'liver' named entity 'adhesion' named entity 'immunomodulatory' named entity 'leukocyte' named entity 'Google Scholar' named entity 'antiviral' named entity 'methyl' named entity 'antioxidant' named entity 'neonates' named entity 'Pentoxifylline' named entity 'ARDS' named entity 'endothelium' named entity 'Hypercoagulable states' named entity 'collagenase' named entity 'Pentoxifylline' named entity 'blood flow' named entity 'lymphocytes' named entity 'fibrosis' named entity 'phosphodiesterase' named entity 'Medline' named entity 'viral pandemic' named entity 'pentoxifylline' named entity 'COVID' named entity 'coronaviruses' named entity 'organ failure' named entity 'antiviral' named entity 'COVID' named entity 'coronavirus' named entity 'COVID-19' named entity 'apoptosis' named entity 'COVID'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software